{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:26:33Z","timestamp":1782390393922,"version":"3.54.5"},"reference-count":29,"publisher":"The Journal of Rheumatology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To identify cutpoints reflecting Patient Acceptable Symptom State (PASS) and Minimal Clinically Important Improvement (MCII) in patient-reported multi-attribute health status classification systems and health status measurements among patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>We identified patients with RA, AS, and PsA from the Norwegian disease-modifying antirheumatic drug (DMARD) register (NOR-DMARD). The patients (n = 4225) had started with DMARD and responded to the PASS and MCII anchoring questions at the 3-month followup examination. Receiver operating characteristics (ROC) curves with 80% specificity and the 75th percentile approach were used to identify PASS and MCII cutpoints in the EuroQol-5 Dimensions (EQ-5D) and the Short-Form-6 Dimensions (SF-6D) indexes, but also in other patient-reported outcomes (joint pain and patient global visual analog scale and Modified Health Assessment Questionnaire).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>The PASS cutpoints estimated with 80% specificity were around 0.70 in EQ-5D in all diseases and around 0.65 in SF-6D. The cutpoints were around 0.65 and 0.60, respectively, when the 75th percentile approach was used. The MCII cutpoints assessed by 80% specificity varied from 0.10 to 0.19 in EQ-5D and from 0.07 to 0.10 in SF-6D.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>The cutpoints for PASS in EQ-5D and SF-6D indicate that PASS corresponds to a health-related quality of life that is far from perfect health. Somewhat different cutpoints were identified for both PASS and MCII with 80% specificity versus the 75th percentile method.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.090449","type":"journal-article","created":{"date-parts":[[2009,12,2]],"date-time":"2009-12-02T02:02:08Z","timestamp":1259719328000},"page":"26-31","source":"Crossref","is-referenced-by-count":68,"title":["Identification of Cutpoints for Acceptable Health Status and Important Improvement in Patient-Reported Outcomes, in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis"],"prefix":"10.3899","volume":"37","author":[{"given":"MARIA KNOPH","family":"KVAMME","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"IVAR S\u00d8NB\u00d8","family":"KRISTIANSEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ELISABETH","family":"LIE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TORE KRISTIAN","family":"KVIEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2009,12,1]]},"reference":[{"key":"2018112909214810000_37.1.26.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.064287"},{"key":"2018112909214810000_37.1.26.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.019224"},{"key":"2018112909214810000_37.1.26.3","first-page":"86","article-title":"Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis","volume":"33","author":"Zink","year":"2006","journal-title":"J Rheumatol"},{"key":"2018112909214810000_37.1.26.4","first-page":"1188","article-title":"Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders","volume":"34","author":"Tubach","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909214810000_37.1.26.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2007.05.004"},{"key":"2018112909214810000_37.1.26.6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/ard.2007.079798","article-title":"Minimal clinically important improvement\/difference (MCII\/MCID) and patient acceptable symptom state (PASS): what do these concepts mean?","volume":"66","author":"Kvien","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2018112909214810000_37.1.26.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.091454"},{"key":"2018112909214810000_37.1.26.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.077503"},{"key":"2018112909214810000_37.1.26.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.22469"},{"key":"2018112909214810000_37.1.26.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.22342"},{"key":"2018112909214810000_37.1.26.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.24282"},{"key":"2018112909214810000_37.1.26.12","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"2018112909214810000_37.1.26.13","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(96)00822-6"},{"key":"2018112909214810000_37.1.26.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.5.551"},{"key":"2018112909214810000_37.1.26.15","doi-asserted-by":"publisher","DOI":"10.1002\/hec.866"},{"key":"2018112909214810000_37.1.26.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-6296(01)00130-8"},{"key":"2018112909214810000_37.1.26.17","first-page":"941","article-title":"The responsiveness of generic health status measures as assessed in patients with rheumatoid arthritis receiving infliximab","volume":"30","author":"Russell","year":"2003","journal-title":"J Rheumatol"},{"key":"2018112909214810000_37.1.26.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"2018112909214810000_37.1.26.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780261107"},{"key":"2018112909214810000_37.1.26.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.21209"},{"key":"2018112909214810000_37.1.26.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(02)00435-3"},{"key":"2018112909214810000_37.1.26.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.22110"},{"key":"2018112909214810000_37.1.26.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.patrec.2005.10.010"},{"key":"2018112909214810000_37.1.26.24","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.023028"},{"key":"2018112909214810000_37.1.26.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0277-9536(01)00358-6"},{"key":"2018112909214810000_37.1.26.26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/33.7.655"},{"key":"2018112909214810000_37.1.26.27","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.069690"},{"key":"2018112909214810000_37.1.26.28","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-004-6012-0"},{"key":"2018112909214810000_37.1.26.29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39265.679375.80"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.090449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T17:37:29Z","timestamp":1543513049000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.090449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2009,12,29]]},"published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.3899\/jrheum.090449"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.090449","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,1]]}}}